JPMorgan Chase & Co. Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $675.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective increased by JPMorgan Chase & Co. from $575.00 to $675.00 in a report issued on Friday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

Other research analysts have also issued reports about the stock. Mizuho raised their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. BTIG Research boosted their target price on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Citigroup increased their price target on Intuitive Surgical from $567.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $549.00 to $630.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $583.83.

Intuitive Surgical Trading Down 4.0 %

NASDAQ:ISRG opened at $584.05 on Friday. Intuitive Surgical has a 12 month low of $364.17 and a 12 month high of $616.00. The business’s 50-day moving average is $546.03 and its 200 day moving average is $503.38. The company has a market capitalization of $208.03 billion, a P/E ratio of 93.90, a P/E/G ratio of 5.19 and a beta of 1.39.

Insiders Place Their Bets

In related news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This trade represents a 42.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jamie Samath sold 108 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at $4,746,819.42. This trade represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,475 shares of company stock valued at $22,070,807. 0.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Intuitive Surgical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Berbice Capital Management LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter worth $26,000. Godsey & Gibb Inc. grew its position in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the period. MidAtlantic Capital Management Inc. purchased a new position in shares of Intuitive Surgical during the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at about $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical in the third quarter worth about $38,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.